Abstract: This paper presents a tutorial on the Tracking, Telemetry, and Command (TT&C) for spacecraft and satellite missions. In particular, it provides a thorough summary of the design of the TT&C, ...

本仓库用来存放 B 站课程 《现代 C++ 模板教程 2024》的教案、代码，和作业。 任何组织和个人遵守 CC BY-NC-ND 4.0 ...

franky is a high-level control library for Franka robots, offering Python and C++ support. By providing a high-level control interface, franky eliminates the need for strict real-time programming at 1 ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, Recursion announced positive Phase 1b/2 results for REC-4881, which is its ...

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

Abstract: Approximate computing, frequently used in error tolerant applications, aims to achieve higher circuit performances by allowing the possibility of inaccurate ...

Cathie Wood’s ARK ETF published their daily trades for Friday, December 19th, 2025, showcasing significant activity in several key stocks. Leading the trades was a substantial sale of 23,110 shares of ...

昨日大涨11.4%的Recursion(RXRX.US)盘前续涨3.8%。消息上，摩根大通将Recursion Pharmaceuticals的评级由“中性”上调至“增持”，理由是 ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from ...

Investing.com - 摩根大通周三将Recursion Pharmaceuticals (NASDAQ:RXRX)评级从"中性"上调至"增持"，同时将目标价从10.00美元上调至11.00美元。该股目前交易价格为4.20美元，根据摩根大通的新目标价，潜在上涨空间超过160%，尽管根据InvestingPro数据显示，该股在过去一周下跌了 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...